BICO subsidiary Cytena has reached a $10 million agreement with Applitech Pharmaceutical Equipment Technology to distribute its single-cell isolators in China with the intent to develop novel treatments such as gene therapies, biosimilars and monoclonal antibodies. The two-year deal encompasses the use of almost 100 of Cytena’s single-cell isolators, including the UP.SIGHT devices. China represents the world’s second-largest…